shPSMD3 lentiviral vector

shPSMD3 lentiviral vector is an experimental gene therapy agent designed to silence the expression of the 26S proteasome non-ATPase subunit 3 (PSMD3). PSMD3 is a critical component of the 19S regulatory complex of the 26S proteasome, which is often overexpressed in various hematologic malignancies and solid tumors. The vector delivers a doxycycline-inducible small-hairpin RNA (shRNA) that targets PSMD3 mRNA for degradation. In preclinical studies of FLT3-mutated acute myeloid leukemia (AML), knockdown of PSMD3 has been shown to inhibit cell proliferation, induce cell cycle arrest, and suppress the activation of key oncogenic signaling pathways, including STAT3, STAT5, and mTOR. Research conducted at the Texas Tech University Health Sciences Center suggests that targeting the 19S regulatory complex via PSMD3 inhibition may offer a therapeutic strategy with potentially lower toxicity compared to traditional 20S proteasome inhibitors like bortezomib.

Other names

shPSMD3 lentiviral vectorshPSMD-3 lentiviral vectorshPSMD 3 lentiviral vectordox-inducible shPSMD3 lentiviral vector